Evidence map›Paper›PMID 32027715›Full record

ArticlePloS one2020

Serotype and clonal distribution dynamics of invasive pneumococcal strains after PCV13 introduction (2011-2016): Surveillance data from 23 sites in Catalonia, Spain.

Guillermo Ludwig, Selene Garcia-Garcia, Miguel Lanaspa, Pilar Ciruela, Cristina Esteva, Mariona Fernandez de Sevilla, Alvaro Diaz-Conradi, Carmina Marti, Montse Motje, Carme Galles and 10 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Genomic epidemiology ofFrontiers in cellular and infection microbiology · 2026
    Article
  3. Development of semisynthetic saponin immunostimulants.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2024
    Review
  4. [Serotype Distribution ofJugan geon-gang gwa jilbyeong · 2023
    Article
  5. Serotype Distribution and Antimicrobial Resistance ofAnnals of laboratory medicine · 2023
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Microbial genomics · 2021
    Article
  12. Article
  13. Article
  14. Genomic Characteristics of InvasiveBioinformatics and biology insights · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 9 institutions in 1 country.

Guillermo LudwigInstitut de Recerca Sant Joan de Deu, Hospital Sant Joan de Deu, Barcelona, Spain.ORCID 0000-0001-9465-3085
Selene Garcia-GarciaInstitut de Recerca Sant Joan de Deu, Hospital Sant Joan de Deu, Barcelona, Spain.
Miguel LanaspaInstitut de Recerca Sant Joan de Deu, Hospital Sant Joan de Deu, Barcelona, Spain.
Pilar CiruelaCIBER de Epidemiologia y Salud Publica (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain.
Cristina EstevaInstitut de Recerca Sant Joan de Deu, Hospital Sant Joan de Deu, Barcelona, Spain.
Mariona Fernandez de SevillaInstitut de Recerca Sant Joan de Deu, Hospital Sant Joan de Deu, Barcelona, Spain.
Alvaro Diaz-ConradiHospital de Nens, Barcelona, Spain.
Carmina MartiHospital General de Granollers, Granollers, Spain.
Montse MotjeHospital Universitari de Girona Dr. Josep Trueta, Girona, Spain.
Carme GallesHospital Sant Jaume, Calella, Spain.
Montse MortaHospital Sant Joan de Deu de Manresa, Barcelona, Spain.
Conchita IzquierdoAgencia de Salut Publica de Catalunya (ASPCAT), Generalitat de Catalunya, Barcelona, Spain.
Fernando Moraga-LlopHospital Universitari Vall d'Hebron, Barcelona, Spain.
Magda CampinsHospital Universitari Vall d'Hebron, Barcelona, Spain.
Luis SallerasCIBER de Epidemiologia y Salud Publica (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain.
Mireia JaneCIBER de Epidemiologia y Salud Publica (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain.
Angela DominguezCIBER de Epidemiologia y Salud Publica (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain.
Juan Jose Garcia-GarciaInstitut de Recerca Sant Joan de Deu, Hospital Sant Joan de Deu, Barcelona, Spain.ORCID 0000-0002-3483-528X
Carmen Muñoz-AlmagroInstitut de Recerca Sant Joan de Deu, Hospital Sant Joan de Deu, Barcelona, Spain.ORCID 0000-0001-5586-404X
Catalan Study Group of Invasive Pneumococcal Disease
Hospital Sant Joan de Déu Barcelona · ESGeneralitat de Catalunya · ESInstituto de Salud Carlos III · ESHospital de Nens de Barcelona · ESHospital General de Granollers · ESHospital Sant Jaume de Calella · ESHospital Universitari de Girona Doctor Josep Trueta · ESVall d'Hebron Hospital Universitari · ESVall d'Hebron Institut de Recerca · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe objective of this study is to describe incidence and shifts of serotype and clonal distribution of invasive Streptococcus pneumoniae strains in four different age groups (<5 years, 5-17 years, 18-64 years and >65 years) during a period of intermediate PCV13 vaccination coverage (2011-2016) in Catalonia, Spain.

methodsWe included all pneumococcal strains systematically sent to the Catalan support laboratory for molecular surveillance of invasive pneumococcal disease (IPD) located at Hospital Sant Joan de Deu, Barcelona. Two study periods were considered: 2011-13, early PCV13 vaccination period (EVP) and 2014-2016, late vaccination period (LVP).

resultsA total of 2142 strains were included in the study. Five years after intermediate introduction of PCV13 in our population, a significant decrease of overall incidence of IPD in children <5 years was observed (incidence rate ratio 0.5, 95% confidence interval 0.4-0.8). However, in seniors older than 65 years, a significant increase of overall incidence of IPD was observed (IRR 1.4, 95% CI 1.1-1.7). The contribution of PCV13 vaccine serotypes to IPD declined significantly in all age groups: from 59% to 38.1% in <5 years; 82.7% to 59% in 5-17 years, 47.8% to 34.1% in 18-64 years and 48.2% to 37% in >65 years. Results found when comparing both periods were consistent with IRRs observed year by year. In children <5 years, the three major serotypes detected were 1, 24F and 19A in EVP vs 24F, 14 and 10A in LVP. Among patients 5-17 years the first three serotypes were 1, 12F and 14 both in EVP and LVP. Among adults 18-64, the three major serotypes detected were 1, 12F and 8 vs 8, 12F and 3, respectively. Finally, in patients >65 years the most frequently isolated serotypes were 3, 19A and 7F vs 3, 14 and 12F, respectively. Regarding clonal complexes (CCs) expressing mainly PCV13 serotypes, significant decreases of the proportions of CC306, CC191 and CC320 were observed, while CC156 showed a significant increase. As for CCs expressing mostly non-PCV13 serotypes, significant increases in ST989, CC53 and CC404 were showed.

conclusionsDespite low vaccine coverage in our setting a significant decrease of incidence of IPD was observed in children younger than 5 years. The modest indirect protection against vaccine serotypes causing IPD in elderly indicate the need for the inclusion of more serotypes in future high-valent PCV and vaccinating old adults should be considered.

Indexed as

Chronic Disease IndicatorsSerogroupAdolescentAdultAgedChildChild, PreschoolFemaleHumansMaleMiddle AgedPneumococcal InfectionsPneumococcal VaccinesSerotypingSpainStreptococcus pneumoniae13-valent pneumococcal vaccinePneumococcal Vaccines

Identifiers

PMID32027715
PMCPMC7004304
OpenAlexW3004509033

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.